Industry
Pharmaceuticals
Topic
Bankruptcy
People
Find news about people
Organizations
Find news about organizations
Alumni
Find news on alumni of any org
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
Bankruptcy in Pharmaceuticals
... news sites Spirited Media, which owns three local news sites including The Incline in Pittsburgh, has cut staff saying it is not generating enough revenue ...
... the deal. Celcuity plans to list on the Nasdaq as "CELC." [ts_bullet_primary] Krystal Biotech , a Pittsburgh, Penn.-based therapy company focused on dermatological diseases, priced ...
... due to the failure of its hepatitis B drug candidate, where GlobeImmune Inc. (GBIM) goes from here is still up in air. The company does ...
... According to its CEO, Diadexus Inc. (DDXS) is planning to follow in the footsteps of two of its ...
... the Novato, Calif., drug company said in a statement Tuesday. Cambridge-based Sarepta Therapeutics Inc. is developing a rival drug to treat the deadly muscle disease ...
... oligonucleotide and immune-oncology-based ACCURINS®. BIND has announced ongoing collaborations with Pfizer Inc., AstraZeneca AB, F. Hoffmann-La Roche Ltd., Merck & Co., or Merck (known as ...
... in 2014, according to the new AFL-CIO report. Medicaid gets $25M from Pfizer deal The state attorney general says Ohio’s Medicaid program will get nearly ...
... the US Senate on Wednesday and answer questions about his relationship with Valeant Pharmaceuticals. Valeant's outgoing CEO, Michael Pearson, and its former interim CEO, Howard ...
... . Here are the top Wall Street headlines at midday: IT'S OFFICIAL: Valeant has a new CEO - Valeant has named Joseph Papa as its ...
... SIGA Technologies, Inc. (SIGA) (OTCMKTS:SIGAQ), a company specializing in the commercialization of solutions for ...
... lawsuits with the Framingham company seeking to block the merger. Astellas claims Ocata for $379 million Overcoming fierce opposition from disgruntled investors, Japanese drug maker ...
... physician group based in Covington. St. E agreed to pay $600,000, and HealthPoint agreed to pay $50,000. About $100,000 of the purchase price went toward ...
... Nuo Therapeutics, Inc. (OTCQX:NUOT) (the "Company") announced today that it has filed a voluntary ...
... surging developing economies that helped lift foreign sales slowed dramatically. Irish drugmaker Shire ups bid for Baxalta TRENTON, N.J. -- Irish drugmaker Shire PLC's second ...
... a number of its peers dropped. In the latter group falls Valeant Pharmaceuticals International Inc. , another deal-hungry drug maker whose trajectory closely tracked Allergan’s ...
... to disgruntled MSNB investors. Following his arrest, Shkreli resigned as CEO of Turing Pharmaceuticals, another privately held biotechnology company that he founded. In September, controversy ...
... SIGA Technologies, Inc. a company specializing in the commercialization of solutions for serious unmet ...
... SIGA Technologies, Inc., a company specializing in the commercialization of solutions for serious unmet ...
... status of its transaction with Jardin de Invierno SA, trading as Winter Garden Biosciences. WG is an emerging agriculture bioscience and biotechnology company in which ...
... the end of Teva Pharmaceutical Industries Ltd's (TEVA) $40.5 billion acquisition of Allergan's generic business. Teva clinched that deal after failing in a hostile bid ...
... la crème of management. Worldwide Branding LLC on July 22 awarded former Dendreon Corp. CEO and president W. Thomas Amick the title of executive of ...
... Bethlehem Qualified: 2000 Made partner: 2009 Key deals: Novartis' three-part transaction with GlaxoSmithKline, including the setting up of a consumer healthcare joint venture; IPOs of ...
... 15% in the May period. Shares dropped 2.7% to $68.46 premarket. Merrimack Pharmaceuticals Inc. and Baxter International Inc.'s Baxalta unit said their new drug application ...
... organic ketchup bottle was introduced in response to demand from larger families. Teva now owns 18.1 million shares, 3.69% stake in Mylan Teva Pharmaceutical Industries ...
... Dendreon Corp. has left court protection. The defunct Seattle biotechnology company on Wednesday, ...
Want to see the full history of news or view news on a particular date? Upgrade to RelSci Professional now!
Start My Free Trial ➤